Verastem Oncology announced that the first patient has been dosed in a Phase 1/2 trial in China, conducted by GenFleet Therapeutics, evaluating GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in the development and potential commercialization of product candidates, including avutometinib in combination with other compounds, including defactinib, LUMAKRAS and others; the uncertainties inherent in research and development, such as negative or unexpected results of clinical trials, the occurrence or timing of applications for product candidates that may be filed with regulatory authorities in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any such applications that may be filed for product candidates, and, if approved, whether product candidates will be commercially successful in such jurisdictions; ability to obtain, maintain and enforce patent and other intellectual property protection for product candidates; the scope, timing, and outcome of any legal proceedings; decisions by regulatory authorities regarding trial design, labeling and other matters that could affect the timing, availability or commercial potential of product candidates; whether preclinical testing of product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials; that the timing, scope and rate of reimbursement for product candidates is uncertainty; the market opportunities of drug candidates are based on internal and third-party estimates which may prove to be incorrect; that third-party payors (including government agencies) may not reimburse; that there may be competitive developments affecting product candidates; that data may not be available when expected; that enrollment of clinical trials may take longer than expected, which may delay the development programs, including delays in submission or review by the FDA of NDA submission in recurrent KRAS mutant LGSOC if enrollment in confirmatory trial is not well underway at the time of submission; that product candidates will cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles as compared to their levels of efficacy; that maybe unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so; that the mature RAMP 201 data and associated discussions with the FDA may not support the scope of rolling NDA submission for the avutometinib and defactinib combination in LGSOC, including with respect to KRAS wild type LGSOC; that product candidates may experience manufacturing or supply interruptions or failures; that any of third-party contract research organizations, contract manufacturing organizations, clinical sites, or contractors, among others, who rely on fail to fully perform; that face substantial competition, which may result in others developing or commercializing products before or more successfully than do which could result in reduced market share or market potential for product candidates; that will be unable to successfully initiate or complete the clinical development and eventual commercialization of product candidates; that the development and commercialization of product candidates will take longer or cost more than planned, including as a result of conducting additional studies or decisions regarding execution of such commercialization; that we may not have sufficient cash to fund our contemplated operations, including certain of our product development programs; that we may not attract and retain high quality personnel; that or Chugai Pharmaceutical Co. Ltd. will fail to fully perform under the avutometinib license agreement; that total addressable and target markets for our product candidates might be smaller than we are presently estimated; that Secura Bio Inc. will fail to fully perform Under the asset purchase agreement with Secura Bio Inc., including in relation to milestone milestone milestone milestone milestone milestone milestone.